Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT03180736Phase 3Completed
- Start
- Jun 2017
- Primary completion
- Jul 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of daratumumab in multiple myeloma (MM). Started Jun 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03180736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03180736.